Repurposing of N-Acetylcysteine for the Treatment of Dengue Virus-Induced Acute Liver Failure.

IF 2.6 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatic Medicine : Evidence and Research Pub Date : 2020-11-03 eCollection Date: 2020-01-01 DOI:10.2147/HMER.S263840

Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Filmon Beyenne Demoz

{"title":"Repurposing of N-Acetylcysteine for the Treatment of Dengue Virus-Induced Acute Liver Failure.","authors":"Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Filmon Beyenne Demoz","doi":"10.2147/HMER.S263840","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of dengue infection-induced acute liver damage is increasing from time to time. Since it has no specific antiviral treatment in the world, people in endemic areas suffer more from dengue disorders. Thus, there is a need for searching options for the treatment of dengue-induced acute liver failure. N-acetylcysteine, which is used for the treatment of nasal congestion disorder and paracetamol overdose toxicity, could be used as a definitive therapy for dengue virus-induced acute liver disease. Therefore, this review discusses the therapeutic use of N-acetylcysteine for dengue-induced acute liver disease. Various case reports and case series showed that patients received NAC recovered from their clinical status. Additionally, a preclinical study showed that N-acetylcysteine has anti-dengue virus activity. Thus, N-acetylcysteine could be used as a definitive therapy in dengue virus-induced hepatitis. This might encourage researchers to further investigate the importance of N-acetylcysteine for dengue virus-induced hepatitis.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"12 ","pages":"173-178"},"PeriodicalIF":2.6000,"publicationDate":"2020-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/HMER.S263840","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Medicine : Evidence and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HMER.S263840","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

The prevalence of dengue infection-induced acute liver damage is increasing from time to time. Since it has no specific antiviral treatment in the world, people in endemic areas suffer more from dengue disorders. Thus, there is a need for searching options for the treatment of dengue-induced acute liver failure. N-acetylcysteine, which is used for the treatment of nasal congestion disorder and paracetamol overdose toxicity, could be used as a definitive therapy for dengue virus-induced acute liver disease. Therefore, this review discusses the therapeutic use of N-acetylcysteine for dengue-induced acute liver disease. Various case reports and case series showed that patients received NAC recovered from their clinical status. Additionally, a preclinical study showed that N-acetylcysteine has anti-dengue virus activity. Thus, N-acetylcysteine could be used as a definitive therapy in dengue virus-induced hepatitis. This might encourage researchers to further investigate the importance of N-acetylcysteine for dengue virus-induced hepatitis.

查看原文本刊更多论文

n -乙酰半胱氨酸用于治疗登革病毒诱导的急性肝衰竭。

登革热感染引起的急性肝损伤的流行率不断上升。由于世界上没有专门的抗病毒治疗方法，流行地区的人们更容易患登革热疾病。因此，有必要寻找治疗登革热引起的急性肝衰竭的方法。n -乙酰半胱氨酸用于治疗鼻塞障碍和扑热息痛过量毒性，可作为登革热病毒引起的急性肝病的最终治疗方法。因此，本文综述了n -乙酰半胱氨酸治疗登革热引起的急性肝病的应用。各种病例报告和病例系列表明，接受NAC治疗的患者从临床状态恢复。此外，一项临床前研究表明，n -乙酰半胱氨酸具有抗登革热病毒活性。因此，n -乙酰半胱氨酸可作为登革热病毒引起的肝炎的决定性治疗药物。这可能鼓励研究人员进一步研究n -乙酰半胱氨酸对登革热病毒引起的肝炎的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Medicine : Evidence and Research GASTROENTEROLOGY & HEPATOLOGY-

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease Investigation and treatment of hepatic disease Pharmacology of drugs used for the treatment of hepatic disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered. As of 1st April 2019, Hepatic Medicine: Evidence and Research will no longer consider meta-analyses for publication.